1-866-598-7166

A Study of Tazemetostat in Patients with Renal Medullary Cancer

Trial ID: NCT02601950
Kidney Cancer Type: Renal medullary cancer


Background:

Medullary tumours and Rhabdoid tumours are rare forms of kidney cancer. They are typically treated using very different medications than the ones used for the more common clear cell kidney cancer.

Tazemetostat is an experimental anti-cancer treatment that inhibits a molecule called EZH2. This prevents cancer cells from turning on their genes responsible for growth and division.


The Trial:

This study will investigate the safety and effectiveness of Tazemetostat for treating patients with medullary or rhabdoid kidney cancer. Different doses of Tazemetostat will be used to determine the optimal dosage.


Basic Eligibility:

  • Medullary or Rhabdoid Kidney Cancer
  • Age 6 months – 18 years
  • No further standard treatment options available

Additional eligibility criteria will apply. Please speak to your doctor.

 

Find out more about this study.
Hospital / Cancer CentrePrincipal InvestigatorLocationTrial Status
Hospital / Cancer CentrePrincess Margaret Cancer Centre | University Health Network Principal InvestigatorDr Abha Gupta LocationToronto, ON Trial StatusRecruiting
Hospital / Cancer CentreAlberta Health Services Principal Investigator LocationEdmonton, AB Trial StatusCompleted
Hospital / Cancer CentreMcGill University Health Centre - Royal Victoria Hospital Principal Investigator LocationMontreal, QC Trial StatusCompleted
Do NOT follow this link or you will be banned from the site!